- Reuters•2 hours ago
The U.S. Food and Drug Administration (FDA) on Tuesday approved Roche Holding AG's multiple sclerosis (MS) drug Ocrevus, putting the potential blockbuster drug back on track after a delay caused by regulators' concerns over manufacturing issues. The infusible drug, known chemically as ocrelizumab, becomes the first U.S.-approved medicine for the primary progressive form of the neurological disease (PPMS). It is also approved to treat the most common form of the disease, known as relapsing-remitting multiple sclerosis (RRMS).
- TheStreet.com•8 hours ago
The Roche drug, Ocrevus, secured FDA approval for two forms of multiple sclerosis.
- Business Wire•9 hours ago
FDA Approves Genentech’s OCREVUS™ (Ocrelizumab) for Relapsing and Primary Progressive Forms of Multiple Sclerosis
Genentech, a member of the Roche Group , announced today that the U.S. Food and Drug Administration approved OCREVUS™ as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis.
RHHBY : Summary for ROCHE HLDG LTD SPONS - Yahoo Finance
Roche Holding AG (RHHBY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||32.00 - 32.25|
|52 Week Range||25.25 - 33.77|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||23.19|
|Dividend & Yield||1.02 (3.16%)|
|1y Target Est||N/A|